Diabetes

Chromium picolinate may benefit patients with insulin resistance

Published in Obesity and Diabetes Week, December 22nd, 2003

Nutrition 21, Inc. (NASDAQ: NXXI), a developer of chromium-based nutritional products, presented results from research studies on two of its novel products containing chromium picolinate, at the first-ever Annual World Congress on Insulin Resistance Syndrome, held in Los Angeles.

According to the American Academy of Clinical Endocrinologists (AACE), a co-sponsor of the Congress, insulin resistance syndrome (also identified as metabolic syndrome) is a physiological metabolic problem, characterized by decreased tissue sensitivity to the action of insulin. Most people with insulin resistance are able to secrete enough insulin to maintain non-diabetic glucose levels, but...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2003-12-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry